Shopify posts massive 34% growth in strong quarter
Shopify (NASDAQ:SHOP) reported second-quarter revenue of $3.58 billion, up 34%, as merchant activity increased across its platform.
Shopify (NASDAQ:SHOP) reported second-quarter revenue of $3.58 billion, up 34%, as merchant activity increased across its platform.
Lilly (NYSE:LLY) reported second-quarter revenue of $23 billion, up 48%, as demand for Mounjaro and Zepbound supported volume growth.
Dan Ives, partner and senior managing director at Yorkville Ives & Co., examines the first quarterly report from SpaceX as the company disclosed higher-than-expected spending on its artificial intelligence business.
The Walt Disney Company (NYSE:DIS) reported fiscal third-quarter revenue of $25.25 billion, up 7%, as Experiences and Entertainment grew.
Bloomin’ Brands (NASDAQ:BLMN) reported second-quarter revenue of $1.016 billion, up 1.3%, as higher comparable restaurant sales offset restaurant closures.
Owens Corning (NYSE:OC) reported second-quarter net sales from continuing operations of $2.76 billion, broadly unchanged from the previous year.
Circle Internet Group (NYSE:CRCL) reported second-quarter revenue and reserve income of $701 million, up 7%, as USDC activity expanded.
BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.705 billion, up 30%, as BRUKINSA sales expanded globally.
Clear Secure (NYSE:YOU) reported second-quarter revenue of $277.8 million, up 26.6%, while Total Bookings increased 32.8% to $295.9 million.
Primo Brands (NYSE:PRMB) reported second-quarter net sales of $1.80 billion, up 3.8%, as premium and regional spring water brands supported growth.
Novo Nordisk Chief Executive Officer Mike Doustdar says the profitability of its popular Wegovy weight-loss pill is "decent" and will continue to improve. "If that was not the case, we would not be launching the product in more and more markets," he tells Bloomberg Television.
Novo Nordisk A/S Chief Executive Officer Mike Doustdar talks about the company's performance as its popular Wegovy weight-loss pill disappointed investors with sales that failed to live up to the hype. "We are not right now discussing further discounts," Doustdar tells Bloomberg's Francine Lacqua.